Turnstone Biologics Corp - TSBX STOCK NEWS

Welcome to our dedicated page for Turnstone Biologics news (Ticker: TSBX), a resource for investors and traders seeking the latest updates and insights on Turnstone Biologics stock.

Turnstone Biologics Corp (TSBX) delivers innovative Selected TIL therapies targeting solid tumors through precision immunotherapy. This news hub provides investors and industry observers with essential updates on clinical advancements, strategic partnerships, and corporate developments shaping the future of cancer treatment.

Access authoritative reporting on TSBX's TIDAL-01 and TIDAL-02 clinical trials, regulatory milestones, and scientific breakthroughs. Our curated news collection ensures you stay informed about key events including trial results, manufacturing expansions, and peer-reviewed research publications.

Discover updates across critical categories: Phase 1/2 clinical data readouts, intellectual property developments, executive leadership changes, and collaborations with academic institutions. Each update is vetted for relevance to TSBX's mission of advancing next-generation tumor-infiltrating lymphocyte therapies.

Bookmark this page for streamlined access to Turnstone Biologics' verified announcements. Combine real-time updates with in-depth analysis of how TSBX's Selected TIL technology compares to conventional immunotherapy approaches in oncology.

03/21/2024 05:06 PM

News

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Recent Business Highlights

Rhea-AI Summary

Turnstone Biologics Corp. (Nasdaq: TSBX) reports financial results for Q4 and full year 2023, highlighting progress in the TIDAL-01 program with Phase 1 trials ongoing. The company aims to develop Selected TIL therapy for solid tumors, expecting initial clinical data by mid-2024. Recent business highlights include expanding TIDAL-01 trials to cover additional solid tumor types and presenting promising preclinical data at SITC 2023. Turnstone also strengthened its Scientific Advisory Board with the addition of Dr. Jeffrey S. Weber, enhancing expertise in cancer immunotherapy. Financially, the company ended 2023 with $94.8 million in cash, cash equivalents, and short-term investments, projecting funds to sustain operations until Q2 2025. R&D expenses decreased in Q4 2023 compared to the previous year, while net loss increased due to various factors.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-10.48%

Tags

02/21/2024 06:00 AM

News

Turnstone Biologics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Turnstone Biologics Corp. (TSBX) announced its participation in upcoming investor conferences, including TD Cowen 44th Annual Global Health Care Conference and Leerink Partners Global Biopharma Conference 2024. Sammy Farah, President and CEO, will present at these events to discuss the Company's innovative approach to treating solid tumors with Selected TIL therapy.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

7.49%

Tags

02/20/2024 05:00 PM

News

Turnstone Biologics Announces the Passing of Chief Legal Officer P. Joseph Campisi, Jr., Esq.

Rhea-AI Summary

Turnstone Biologics Corp. (TSBX) announces the passing of Chief Legal Officer P. Joseph Campisi, Jr. due to cancer. The Company mourns his loss but expresses confidence in the management team's ability to uphold his legacy and drive the company's mission forward.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

7.49%

Tags

11/27/2023 06:00 AM

News

Turnstone Biologics to Participate in the Piper Sandler 35th Annual Healthcare Conference

Rhea-AI Summary

Turnstone Biologics Corp. (TSBX) announced that its President and CEO will participate in the Piper Sandler 35th Annual Healthcare Conference in New York, NY. The company is developing a unique approach to treat solid tumors using Selected TIL therapy.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

0.78%

Tags

11/09/2023 09:49 PM

News

Turnstone Biologics Corp. Reports Third Quarter 2023 Financial Results and Provides Recent Business Highlights

Rhea-AI Summary

Turnstone Biologics Corp. (TSBX) reported encouraging preclinical data on its Selected TIL programs for solid tumors at SITC 2023. The lead program, TIDAL-01, is on track in two Phase 1 trials with initial clinical data expected mid-2024. An upsized IPO extends runway into Q2 2025, and the Scientific Advisory Board was strengthened with the appointment of Dr. Jeffrey S. Weber, an internationally recognized cancer immunotherapy expert.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-4.86%

Tags

11/03/2023 06:00 AM

News

Turnstone Biologics Presents Preclinical Data Highlighting Potential for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy in Solid Tumors at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Rhea-AI Summary

Turnstone Biologics Corp. will be presenting preclinical data from its pipeline of programs, including its lead clinical candidate TIDAL-01, at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. The data highlights the potential of Turnstone's differentiated approach to treat solid tumors using selected tumor-infiltrating lymphocyte (Selected TIL) therapy. Key findings include the successful expansion of TIL from metastatic colorectal and gastric cancer patient samples, the development of a neoantigen prioritization pipeline for Selected TIL therapy, the viability of liquid biopsy for detecting somatic variants and prioritizing neoantigens, and the genetic modification of directly selected tumor-reactive TIL to enhance their quality and function.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-2.13%

Tags

10/30/2023 06:00 AM

News

Turnstone Biologics Expands Scientific Advisory Board with Appointment of Dr. Jeffrey S. Weber

Rhea-AI Summary

Turnstone Biologics Corp. has announced the addition of Dr. Jeffrey S. Weber to its Scientific Advisory Board. Dr. Weber, an internationally recognized thought leader in innovative immunotherapies for solid tumors, will provide strategic, scientific, and clinical guidance to advance Turnstone's pipeline of Selected TIL therapies. These therapies aim to selectively expand tumor-reactive T cells and extend the benefits of TILs to various solid tumor types.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

24.12%

Tags

09/28/2023 06:00 AM

News

Turnstone Biologics to Present Preclinical Data for Selected Tumor-Infiltrating Lymphocyte (TIL) Therapy at Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

Rhea-AI Summary

Turnstone Biologics Corp. will present preclinical data for its Selected TIL therapies at the SITC 38th Annual Meeting in November.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

10.36%

Tags

09/01/2023 05:57 PM

News

Turnstone Biologics Corp. Reports Second Quarter 2023 Financial Results and Provides Business Update

Rhea-AI Summary

Turnstone Biologics Corp. successfully closed upsized IPO, raising $88 million in gross proceeds. Cash position expected to fund operations into second quarter of 2025. Two Phase 1 clinical trials of lead program, TIDAL-01, ongoing. Clinical update expected in mid-2024. Pre-clinical data supports ongoing clinical efforts. Cash, cash equivalents, and short-term investments as of June 30, 2023, were $49.2 million. R&D expenses decreased, while G&A expenses increased. Net loss for Q2 2023 was $21.5 million.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-11.83%

Tags

07/21/2023 02:15 AM

News

Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering

Rhea-AI Summary

Turnstone Biologics Corp. announces the pricing of its upsized initial public offering of 6,666,667 shares of common stock at $12.00 per share. The gross proceeds are expected to be $80.0 million. The offering is expected to close on July 25, 2023.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags